Key Highlights
● Eli Lilly edged higher with no company-specific news, outperforming most large pharmaceutical peers.
● Bristol-Myers Squibb, Johnson & Johnson and Pfizer all fell the same day.
● Ginkgo Bioworks surged on continued momentum from its AI drug-discovery Partnership with Lilly.
Eli Lilly edged higher on Monday, Oct. 5, moving with the broader market and holding up better than most big drugmakers on a soft day for health care.
A quiet gain
Eli Lilly (NYSE:LLY) edged higher on Monday, according to market data. No company-specific news was found to explain the move, and the stock appeared to drift up with the wider market.
That was a better showing than many of its large pharmaceutical peers managed. Health care was the weakest sector in the S&P 500 at midday and finished with a modest decline.
Pharma under pressure
Several big drugmakers fell. Merck (NYSE:MRK) was the worst stock in the Dow. Bristol-Myers Squibb (NYSE:BMY) slid after Leerink Partners analyst David Risinger downgraded it to Market Perform from Outperform and cut his target to $59 from $73, citing risks in its pipeline. "We changed our Investment thesis after conducting more detailed assessments of key pipeline candidates reading out over the next several months," Risinger said.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also fell. Against that backdrop, Lilly's small gain left it among the steadier names in big pharma.
Lilly's place in the market
Eli Lilly has become one of the most valuable drugmakers in the world, driven by its diabetes and obesity treatments built on GLP-1 science, along with medicines for cancer, immunology and neuroscience. Because of its size, its moves carry real weight in health care indexes.
Lilly also cropped up indirectly in Monday's small-cap trading. Ginkgo Bioworks (NYSE:DNA) surged in a move tied to continued momentum from an AI drug-discovery partnership with Lilly announced on Sept. 15. No new Ginkgo release was found for Monday.
Not everything in the sector was weak, either. Life-science tools stocks rallied, led by Charles River Laboratories (NYSE:CRL), which climbed sharply to a 52-week high. Vaccine names were busy too: Vaxcyte (NASDAQ:PCVX) soared after its VAX-31 pneumococcal vaccine met all its main goals in a pivotal Phase 3 trial, and Moderna (NASDAQ:MRNA) rallied ahead of joining the Nasdaq-100.
Records for the Nasdaq
The broader market finished higher. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90.
That came even as the 10-year Treasury Yield rose to its highest close since 2002. The ISM services survey showed prices paid at their highest since July 2022. But Friday's jobs report, with only 29,000 positions added in September, cut the odds of another Fed rate hike in October to roughly one in four or less, down from better than even a week earlier.
Interactive Brokers senior economist Jose Torres said: "Labour conditions are stable overall, but Friday's downward revisions signal that the US economy has lost jobs in two out of the nine months year to date."
Oil eased, with Brent settling at $100.32 a barrel, after G7 nations agreed to release 100 million barrels of crude and diesel from emergency reserves.
What to watch
For Eli Lilly, the next major checkpoint is its quarterly Earnings report, where investors will look for updates on Demand for its diabetes and obesity medicines and on its pipeline.
For the broader market, the Fed releases minutes of its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday and Delta Air Lines Friday. Bank earnings start on Oct. 13, and the Fed's next policy meeting is Oct. 27–28.






Please wait processing your request...